ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
Recognition of the role of the renin-angiotensin-aldosterone system (RAAS) in initiating and maintaining hypertension prompted the development of drugs that disrupt the RAAS, notably the angiotensin-converting enzyme (ACE) inhibitors and, more recently, the angiotensin II receptor blockers (ARBs). This article focuses on the use of ARBs in hypertension management and reviews evidence emerging from clinical trials that ARBs offer target organ protection over and above their antihypertensive activity.
Silverstein
Russell L
RL
Dallas Nephrology Associates, TX, USA. silversteinr@dneph.com
Fenves
Andrew Z
AZ
Ram
C Venkata S
CV
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control*; D018849:Controlled Clinical Trials as Topic; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000517:prevention & control; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000517:prevention & control; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors; D013997:Time Factors; D014481:United States / Q000453:epidemiology
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors